ROMISTERNCT07700238
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 32 words
- Trial sites expanded: 3 → 21 locations
- Start date changed from estimate of Aug 21, 2026 to Oct 15, 2026
- Study title expanded, about 2 words
Notable Recruitment opened Show 4 more changesShow less
- Start date: Jul 20, 2026 to Aug 21, 2026
- Eligibility criteria expanded, about 15 words
- Trial sites expanded: 0 → 3 locations
- Study completion pushed from Sep 14, 2029 to Oct 14, 2029
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants will receive romiplostim administered subcutaneously (SC) in combination with predniso(lo)ne administered orally during Part 1 of the study. Participants who complete Part 1 of the study will enter Part 2 and continue participation for study assessments.
Participants will receive predniso(lo)ne administered orally during Part 1 of the study. Participants who complete Part 1 of the study will enter Part 2 and continue participation for study assessments.
Drugs: Romiplostim, Predniso(lo)ne
Sites
21 sites in 5 countries
Turkey (Türkiye) 5, Germany 4, Hungary 4, Spain 4, United States 4